Illumina, Inc. vs Msci Inc — how do they compare? Illumina, Inc. trades at $193.06 (market cap $29.12B), while Msci Inc trades at $562 (market cap $40.84B). The key difference: Msci Inc is the larger of the two by market cap, and Msci Inc pays a 1.46% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| ILMN | MSCI | |
|---|---|---|
Market Cap | $29.12B | $40.84B |
Sector | Health | Financials |
52-Week High | $205.10 | $643.83 |
52-Week Low | $91.00 | $511.84 |
Enterprise Value | $30.48B | $47.00B |
Dividend Yield | — | 1.46% |
Trailing returns across standard periods
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →